T2 Biosystems, Inc. announced the execution of a territory exclusive distribution agreement in Taiwan. Under the terms of the agreement, T2 Biosystems will sell T2Dx Instruments, along with T2Bacteria, T2Candida and T2Resistance Panels through this distributor. The execution of this distribution agreement includes an initial purchase of three T2Dx Instruments and marks T2 Biosystems? third entry in the Asia-Pacific market during the last 30 days. According to the Asia Pacific Sepsis Alliance, the estimated national sepsis incidences in this region ranges from 120 up to 1,600 per 100,000. The incidence of sepsis is 287 per 100,000 people in Taiwan and a recent analysis estimated the national health expenditure of 33.5 billion NT dollars for sepsis hospitalizations was higher than those for cancer and diabetes, estimated at 23.0 billion and 1.5 billion NT dollars, respectively. T2 Biosystems and its new distribution partner are collaborating with the health authorities in Taiwan to gain regulatory approval and offer patients the higher quality sepsis care available.